SMN1, the causative gene for spinal muscular atrophy (SMA), plays a housekeeping role in the biogenesis of small nuclear RNA ribonucleoproteins. SMN is also present in granular foci along axonal projections of motoneurons, which are the predominant cell type affected in the pathology. These so-called RNA granules mediate the transport of specific mRNAs along neurites and regulate mRNA localization, stability, as well as local translation. Recent work has provided evidence suggesting that SMN may participate in the assembly of RNA granules, but beyond that, the precise nature of its role within these structures remains unclear. Here, we demonstrate that SMN associates with polyribosomes and can repress translation in an in vitro translation system. We further identify the arginine methyltransferase CARM1 as an mRNA that is regulated at the translational level by SMN and find that CARM1 is abnormally up-regulated in spinal cord tissue from SMA mice and in severe type I SMA patient cells. We have previously characterized a novel regulatory pathway in motoneurons involving the SMN-interacting RNA-binding protein HuD and CARM1. Thus, our results suggest the existence of a potential negative feedback loop in this pathway. Importantly, an SMA-causing mutation in the Tudor domain of SMN completely abolished translational repression, a strong indication for the functional significance of this novel SMN activity in the pathology.
INTRODUCTION
Proximal spinal muscular atrophy (SMA) is a common autosomal recessive disease characterized by the selective degeneration of lower a-motor neurons in the anterior horn of the spinal cord (1) . Typical clinical manisfestations are symmetrical muscular weakness, ultimately leading to muscle atrophy, paralysis and death from respiratory distress within 2 years of age (2) . Based on the time of onset and severity, SMA can be divided into five types, with type I being the most severe and most common form (3) . SMA is caused by the disruption of the survival of motor neuron (SMN1) gene (4) , with the level of functional SMN protein in patients inversely correlating with the severity of the disease (5, 6) . SMN exists in all cells as part of a stable macromolecular complex consisting of eight tightly associated 'Gemins' and Unrip (7 -9) . The best characterized function for the SMN complex is its chaperoning role in the cytoplasmic assembly of small nuclear ribonucleoprotein particles (snRNPs), the core components of the pre-mRNA splicing machinery (7 -10) . As this function should be equally important for all cell types, it remains a major question to understand why motoneurons are the most affected cell type in the face of reduced SMN levels. It has been proposed that this may be explained by a greater sensitivity of motoneurons to low snRNA levels and/or splicing defects, including a recently uncovered feedback loop affecting the splicing of SMN2 exon 7 (11 -15) . Alternatively, SMN may play a distinct, snRNP-independent, role(s) in motoneurons. In support of the latter model, SMN is found * To whom correspondence should be addressed. Tel: +1 6135625800; Fax: +1 6135625636; Email: jcote@uottawa.ca # The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com in RNA-containing foci along axons, the so-called neuronal RNA granules, where it interacts with RNA-binding proteins such as hnRNP R/Q, FMRP, KSRP and HuD (16) (17) (18) (19) (20) (21) (22) (23) .
RNA granules regulate several aspects of mRNA fate in neurons, including mRNA transport, mRNA stability and local translation at growth cones and synapses (24) (25) (26) . SMN-deficient motoneurons, cultured from a mouse model of SMA, were shown to have reduced localization of b-actin mRNA in axons and reduced levels of b-actin protein in axonal growth cones (19) . Since hnRNP R/Q and KSRP are known components of the b-actin mRNP complex, it has been speculated that interactions between these proteins and SMN may promote axonal b-actin mRNP assembly, transport and localization (20, 27) . Defects in mRNA stability have also been reported in the face of reduced SMN levels in neuronal cell lines (20) . More recently, it was shown that down-regulation of SMN resulted in reduced levels of HuD and poly(A) + mRNA being present in axonal projections of motoneurons (16, 17) . Using a biochemical fractionation approach, we similarly demonstrated that SMN was required for proper translocation of KSRP and HuD (along with its mRNA targets) into fast-sedimenting sucrose fractions known to contain RNA granules (18) . Such defects in RNA granules assembly and/or function could account, at least in part, for the various neurite outgrowth (in specific model system) and neuromuscular junction maturation, stability and functional defects documented in SMA (19, 20, (28) (29) (30) (31) (32) (33) (34) . Thus, there is so far significant evidence supporting a role of SMN in promoting the proper assembly of neuronal RNA granules. However, whether SMN also plays a functional role within RNA granules remains unclear.
We report here that SMN co-fractionates with polyribosomes in sucrose density gradients and can repress translation in an in vitro translation system. We further identify the arginine methyltransferase CARM1 as an mRNA that is misregulated at the translational level in the absence of SMN. Importantly, naturally occurring Tudor domain mutations found in patients with severe type I SMA greatly reduced the ability of SMN to repress translation. Altogether, this constitutes a novel mechanism through which SMN can regulate gene expression and underscores the importance of proteomic profiling for future SMA studies.
RESULTS

SMN is associated with polyribosomal mRNPs
We have recently shown that a population of fast-sedimenting SMN could be detected after ultracentrifugation in sucrose density gradients (18) . This prompted us to investigate whether SMN is associated with polyribosomes in addition to the well-characterized SMN core complex (8, 9, 35) . For that purpose, cytoplasmic extracts were prepared from motoneuron-derived MN-1 cells and subjected to ultracentrifugation in sucrose density gradients. Each collected fraction was tested for the presence of SMN and the results clearly showed strong signals at 50 s ( Fig. 1A ; left panels, SMN-s), corresponding to the SMN core complex, as previously reported (35) . However, after prolonged exposure of the immunoblots to the films, additional fast-sedimenting SMN species present in fractions containing FMRP and the ribosomal large protein 7 were detected ( Fig. 1A ; left panels, SMN-l). These observations pointed to the possibility that SMN co-fractionated with polyribosomes. Evidence that SMN is present in polyribosomes was obtained after the treatment of polyribosomes with EDTA, a treatment that dissociates the large and small ribosomal subunits and releases mRNPs. A clear shift of SMN toward the lighter fractions was observed supporting the notion that SMN co-fractionates with polyribosomes ( Fig. 1A ; middle panels). To confirm that this pool of SMN is physically associated with the translational machinery, cells were treated with the translational inhibitor puromycin. After such a treatment, virtually all polyribosomes were disrupted as monitored by the UV profile as well as by the distribution of ribosomal L7 protein ( Fig. 1A ; right panels). As expected, FMRP was also shifted to the upper portion of the gradient as previously reported (36) , and a comparable shift was observed for SMN, supporting its association with polyribosomes. Importantly, Gemin2, a protein that forms a stochiometric complex with SMN (37), follows the same distribution in all three conditions tested (i.e. MgCl 2 , EDTA and puromycin treatments). In contrast, Gemin8, Unrip and Sm proteins were not found in polyribosomal fractions even after prolonged exposure of the membranes.
To obtain a much clearer picture of the presence of SMN in the translational machinery, a polyribosome population devoid of the SMN 50S core complex was prepared. This was achieved by sedimenting the cytoplasmic extract at 105 000g over a sucrose pad for 1 h. In these conditions, only a small amount of the 80S monosomes was detected (Fig. 1B ) compared with the major 80S peak depicted in Figure 1A . Under these sedimentation conditions and in the presence of MgCl 2 , no 50S complex could be detected, and a peak of SMN was clearly detected in fractions corresponding to polyribosomes as confirmed by the presence of FMRP and S6 ( Fig. 1B ; left panels), whereas treatment with EDTA shifted SMN as well as FMRP and S6 to the top fractions of the gradients (right panels). Treatments with RNase A also resulted in the complete destruction of polyribosomes, and FMRP as well as SMN were displaced to the top fractions of the gradient (data not shown). This suggests that like FMRP, the sedimentation of SMN heavy polysomal fractions is dependent on the presence of RNA.
Finally, we questioned whether SMN was present in poly(A)+ mRNPs by performing oligo(dT) selection on concentrated polyribosomes treated with EDTA to dissociate ribosomal subunits and to release their associated mRNPs (Fig. 1C) . We first determined the binding of PABP1 to the beads, and in agreement with previous studies we observed that it was eluted from polyribosomal mRNPs at high salt concentrations (38, 39) . On the other hand, SMN is retained onto the oligo (dT) beads and is eluted together with FMRP at 0.5 M NaCl. These results demonstrate that SMN is associated with poly(A)+ mRNPs derived from polyribosomes; however, unlike FMRP, it is not known yet whether SMN binds directly to poly(A)+ mRNA or indirectly through protein partners.
SMN can repress translation of a generic Luciferase reporter
To assess a potential role for SMN in regulating translation, we first used a commercial in vitro transcription/translation Human Molecular Genetics, 2013, Vol. 22, No. 4 669 (TnT) system in rabbit reticulocyte lysates (RRLs). GSTtagged full-length SMN protein was purified from bacteria and added in increasing concentration to standard TnT reactions, using a generic Luciferase reporter as a readout for translation efficiency ( Fig. 2A) . Incubation of GST-SMN in TnT reactions resulted in a dose-dependent reduction in Luciferase activity, whereas GST alone or the RNA-binding protein Staufen 1 as a GST fusion did not have any effects ( Fig. 2A) . This demonstrated that SMN can repress translation of a generic Luciferase reporter in vitro. In order to define which domain(s) of SMN is required for translational repression, wild-type or mutant alleles of SMN were produced using TnT ( Fig. 2B and Supplementary Material, Fig. S1A ), followed by the addition of the same Luciferase reporter as above to assess the effect of each pre-expressed proteins on translation efficiency. Using this approach, SMN levels were Figure 1 . SMN is associated with polyribosomal mRNPs. (A) Cytoplasmic extracts were analyzed by sedimentation velocity through sucrose density gradients in the presence of MgCl 2 after incubation with 30 mM EDTA or after the treatment of the cells with 10 mg/ml puromycin. Note the high levels of SMN in the 50S region as detected after short exposure of the membrane to films (SMN-s), whereas longer exposure (SMN-l) was required to detect SMN in heavy sedimenting structures. The SMN fast-sedimenting species were displaced to the top of the gradients after dissociation with EDTA or treatment of the cells with puromycin. Gemin2 follows the same distribution in the gradient, whereas Gemin8, Unrip and SmB were restricted to slow-sedimenting complexes present at the top of the gradient. FMRP and Ribosomal Protein L7 were used as positive controls. (B) Confirmation that SMN co-fractionates with heavy sedimenting polyribosomes using purified polyribosomes devoid of the 50S complex. FMRP and Ribosomal Protein S6 were used as controls. (C) SMN is retained on oligo(dT) beads loaded with EDTA-dissociated polyribosomes. The column was first washed and proteins were eluted with increasing salt concentrations from 0.3 to 1 M NaCl. The great majority of SMN was recovered in the 0.5 M NaCl fraction, together with FMRP, indicating their presence in poly(A)+ mRNPs. PABP1 was used as an internal marker to validate the binding of the poly(A)+ mRNPs to the oligo(dT). 80S, monosomes; sS, ribosomal small sub-unit; lS, ribosomal large sub-unit. Fig. S1D ). As expected, omitting the CAP greatly reduced overall translation efficiency, and wild-type SMN was still able to inhibit further residual Luciferase mRNA translation observed in the absence of a CAP (Supplementary Material, Fig. S1D ). Altogether, these in vitro translation experiments strongly suggest that an intact Tudor domain is required for SMN to repress translation.
CARM1 expression is mis-regulated at the translational level in DSMN cells
Since SMN was able to repress translation of a generic Luciferase reporter, we next assessed whether it could impact on global translation in cells. As a first approach, cytoplasmic extracts were prepared from control MN-1 cells or from our previously described Smn hypomorphic cell line (18) and were subjected to ultracentrifugation in sucrose density gradients as described above. No striking difference was observed in the overall profile of sedimentation of ribosomal complexes between CTRL and DSMN cell lines (Fig. 2C ), suggesting SMN is not required for the assembly of translating polyribosomes. As a second approach, metabolic radiolabeling using [
35 S]-methionine was performed with MN-1 CTRL and DSMN cell lines. Again comparable overall labeling profiles were obtained with both cell lines (Fig. 2D) , strongly arguing that SMN does not affect global translation and is thus likely to regulate only some specific mRNAs in cells.
We have recently characterized a novel regulatory pathway in motoneuron-derived cells involving the SMN-interacting RNA-binding protein HuD and the arginine methyltransferase CARM1 (18) . While performing those experiments, we noticed that CARM1 protein levels were up-regulated 2-fold in our DSMN cell line (Fig. 3A) . We thus speculated that CARM1 might be a translational target for SMN and sought to determine the mechanism by which CARM1 protein levels were increased under SMA-like conditions. First, CARM1 mRNA levels were quantified using reversetranscription (RT)-qPCR, which demonstrated that there was no significant difference in the steady-state CARM1 mRNA levels between CTRL and DSMN cell lines; and this was true for both nuclear and cytoplasmic pools ( Fig. 3B and C) . We next tested whether CARM1 protein stability was distinct in the face of reduced SMN levels. To investigate this possibility, CTRL and DSMN cell lines were treated with the translational inhibitor cycloheximide (CHX, Fig. 3D ), and total proteins were harvested at different time points in order to study CARM1 protein turnover in both conditions. As seen previously, CARM1 protein levels were higher in the DSMN cell line, but the rate of disappearance of CARM1 protein was comparable between both cell lines ( Fig. 3D) , strongly suggesting that SMN does not regulate CARM1 expression at the level of protein stability.
These results are consistent with CARM1 expression being mis-regulated at the translational level in SMA-like conditions. To test this hypothesis, polyribosomes were analyzed by ultracentrifugation in sucrose density gradients as before and total RNA from each collected fraction was extracted in order to assess the distribution of CARM1 mRNA relative to the ribosomal profile. As a means to quantify the effect of the SMN knockdown on CARM1 mRNA distribution, CARM1 levels were first normalized to GAPDH, and subsequently, the heavy/light polyribosomes ratio was calculated using the mean of 'heavy' polyribosome fractions over the mean of 'light' polyribosome fractions. Strikingly, this resulted in an almost 2-fold increase in the heavy/light polyribosome ratio for CARM1 mRNA in DSMN cells relative to CTRL (Fig. 4A) , which is consistent with increased translation of the CARM1 mRNA in the face of reduced SMN level. To better ascertain the mechanism through which differential expression is achieved, the rate of CARM1 protein synthesis was assessed by using metabolic labeling. CTRL and DSMN MN-1 cell lines were labeled with [
35 S]-methionine for different lengths of time, lysed and subjected to immunoprecipitation with an antibody specific to CARM1 (Fig. 4B) . After normalization to whole-cell extracts levels, the rate of [ 35 S]-methionine incorporation was clearly steeper in DSMN cells compared with CTRL cells (Fig. 4C) . Together, these data strongly suggest that CARM1 expression is increased through translational de-repression in the face of reduced SMN levels.
To confirm that SMN protein levels inversely correlated with CARM1 protein levels, a rescue experiment was performed to restore higher SMN levels into the DSMN cell line. As expected, after transient transfection of a wild-type SMN-GFP construct, CARM1 protein levels observed using immunoblotting were decreased (Fig. 5A , lane 3 and bar graph). Since our previous in vitro experiments have shown that the Tudor domain of SMN was required for its activity as a translational repressor, we wanted to test whether this was also the case in cells, for the translational repression of CARM1 mRNA. As expected, after transient transfection into DSMN cells, CARM1 levels remained unchanged following transient over-expression of the E134K-SMN-GFP mutant (Fig. 5A , lane 2 and bar graph). Lastly, we speculated that the Tudor domain of SMN may be mediating its association with polyribosomes. To test this model, cytoplasmic extracts from DSMN cells expressing E134K-SMN-GFP were subjected to ultracentrifugation through sucrose density gradients and the sedimentation of mutant SMN was assessed by anti-GFP immunoblotting (Fig. 5B) . Strikingly, this experiment revealed that the E134K mutant still co-fractionated with polyribosomes in sucrose density gradients (Fig. 5B) . Thus, our
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results suggest that SMN associates with the translation machinery through a mechanism that is independent of the Tudor domain, which instead might be engaged in the recruitment of a co-factor working together with SMN to regulate translation of specific mRNAs (see the model in Fig. 5C ). . GAPDH was used as loading control. Quantification (right) shows the mean + SEM (n ¼ 6; P , 0.01; Student's t-test) of CARM1/GAPDH ratios. (B) CARM1 mRNA levels do not change in DSMN cells. Total RNAs were isolated from the CTRL and DSMN cell lines. After RT-qPCR and normalization with the mouse cyclophilin B (mCycloB) mRNA, CARM1 levels were expressed relative to CTRL. Data are means + SEM (n ¼ 5). (C) Nucleo-cytoplasmic ratios do not change. RNAs from the nucleus and the cytoplasm were isolated from the CTRL and DSMN cell lines, and CARM1 mRNA level normalized to mCycloB mRNA was quantified by RT-qPCR. Data are means + SEM (n ¼ 3). (D) Protein stability is comparable between the two conditions. Western blot analysis was done to determine CARM1 protein levels following CHX treatment in the CTRL and DSMN cell lines. GAPDH was used as loading control. Quantification shows the mean + SEM (n ¼ 4) of the CARM1/GAPDH ratios.
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SMN represses CARM1 mRNA translation independently of UTRs
Specificity in translational regulation often involves sequences within mRNA 5 ′ and/or 3 ′ UTRs. To determine whether this was the case for the repression of CARM1 mRNA translation by SMN, in vitro translation assays were performed as above, by pre-programming of RRLs with either wild-type SMN or b-Gal as a negative control. As observed previously, increasing SMN by 2-fold in the RRLs led to a reduction of 60% in Luciferase activity, and inserting CARM1 5 ′ and 3 ′ -UTRs in the Luciferase reporter did not result in further repression (Fig. 6A ). This suggests that CARM1 UTRs do not contribute significantly to the mechanism by which SMN represses translation, at least in vitro. To further validate these results in cells, Firefly Luciferase reporters, harboring or not CARM1 UTRs, were transfected along with a Renilla Luciferase reporter into MN-1 control, DSMN or DSMN cell lines in which SMN expression (SMN-GFP fusion construct) was restored. In order to obtain the effect of the CARM1 UTRs, Firefly/Renilla ratios obtained in the presence of CARM1 UTRs were expressed relative to the empty vector for each condition. Again, a comparable ratio was observed in all conditions (Fig. 6B) , suggesting that differential CARM1 expression in the face of reduced SMN levels is not mediated through its UTRs. Taken together, these results suggest that, in cells, specificity should arise through CARM1 coding sequences. Thus, we reasoned that a CARM1-GFP fusion protein expressed from an exogenous plasmid should behave similarly to endogenous CARM1 and be de-repressed upon SMN knock down. To test this hypothesis, MN-1 cells selected to stably express low levels of CARM1-GFP were transiently transfected with a plasmid encoding an shRNA targeting SMN mRNA or an shRNA-negative control. Importantly, this experiment first demonstrated that endogenous CARM1 de-repression could be reproduced through transient SMN knock down (Fig. 6C , compare lanes 1 and 4; CARM1), eliminating the possibility that the previously observed effects might be a consequence of clonal selection. Moreover, de-repression was also observed for CARM1-GFP upon SMN shRNA knock down (Fig. 6C , compare lanes 1 and 4; CARM1-GFP), demonstrating that CARM1 coding sequences are sufficient to observe this effect. CHX treatments were performed as above to show that both CARM1-GFP and endogenous CARM1 protein decay rates were again comparable between the two experimental conditions (Fig. 6C , compare lanes 1 -3 with lanes 4 -6; graphs in Supplementary Material, Fig. S2 ). Lastly, we hypothesized that SMN might bind CARM1 mRNA if it regulates its translation. Therefore, we performed RNA immunoprecipitation experiments with our stable MN-1 cell line cells expressing CARM1-GFP. After immunoprecipitation of SMN, co-immunoprecipitated RNAs were extracted and analyzed by RT-qPCR using primers specific for CARM1 coding sequence (Fig. 6D) . Strikingly, both the endogenous CARM1 and CARM1-GFP fusion mRNAs were enriched in the SMN immunoprecipitate, relative to a control immunoprecipitation (Fig. 6D) , strongly suggesting that SMN interacts directly or is at least present in the CARM1 mRNP.
CARM1 is up-regulated in SMA patient cells and in tissues from SMA mouse models
To confirm that CARM1 up-regulation was also observed in SMA pathological settings, we assessed CARM1 protein levels in tissues obtained from severe SMA model mice. First, an increase in CARM1 expression was observed by immunoblotting in spinal cord lysates from E14.5 type I SMA (Smn 2/2 ;SMN2) model mice (Fig. 7A) . Interestingly, there seems to be a certain threshold of SMN level reduction below which the effect is seen in vivo, as we did not observe significant differences in CARM1 protein levels in heterozygous mice (Fig. 7A) , although those mice are essentially asymptomatic. Second, CARM1 expression was also assessed by indirect immunofluorescence staining in frozen sections from the Smn 2B/2 SMA mouse model (40) . Importantly, in this model, a statistically significant CARM1 up-regulation was observed in lumbar spinal cord motoneurons (Fig. 7B) . Finally, CARM1 expression was assessed in primary fibroblasts derived from a severe type I SMA patient, which revealed protein levels 5-fold higher than in an unaffected individual (Fig. 7C) , although mRNA levels were equivalent (Fig. 7D) . Thus, our results convincingly 
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demonstrate increased CARM1 levels as a novel molecular defect in SMA. It is well-established that CARM1 can function as a transcriptional coactivator (41 -45) and can also influence alternative splicing (46, 47) . Thus, we reasoned that CARM1 up-regulation might impact on gene expression profiles in SMA. In unpublished work parallel to this study, our laboratory has identified transcriptional and splicing targets of CARM1, using genome-wide exon arrays. A pilot screen for a number of these validated CARM1 targets revealed that they were also misregulated in our cell culture model of SMA (Fig. 8) . For example, Gdf11 mRNA was up-regulated 0.4-fold in the MN-1 DSMN cell line relative to control, as determined using RT-qPCR ( Fig. 8A; black bar) . Moreover, alterations in exonic composition were observed for Csdc2 and Cab39l mRNAs in DSMN cells ( Fig. 8B and C ; left panels). Strikingly, these effects were reversed upon CARM1 shRNA knock down (Fig. 8A , white bar; B and C, right panels), strongly suggesting that these molecular defects were the consequence of CARM1 up-regulation in DSMN cells. Overall, these data suggest that aberrant translational up-regulation of CARM1, is a novel molecular mechanism contributing to altered gene expression profiles in SMA.
DISCUSSION
We report in the present study that SMN co-fractionates with polyribosomes in sucrose density gradients and can repress translation of a generic Luciferase reporter in vitro and CARM1 mRNA in motoneuron-derived MN-1 cells. Most importantly, we were able to demonstrate that the SMA-causing E134K mutation completely abolished the capacity of SMN to repress translation, suggesting that loss of this novel function might contribute to the development of the SMA pathology.
SMN is associated with polyribosomal mRNPs
Using ultracentrifugation through sucrose density gradients, we have shown that SMN can be found associated with polyribosomes (Fig. 1A) . Under standard conditions, the bulk of Although SMN's activity as a translational repressor requires an intact Tudor domain, its association with ribosomes is Tudor-independent. This suggests the potential involvement of a co-factor, which in turn might also provide mRNA target specificity (see text for details).
SMN was found sedimenting around 50S, which likely represents the core SMN complex, and longer exposures of the immunoblots were needed to detect polysomal SMN, suggesting it is a sub-fraction of total cellular SMN that co-fractionates with polyribosomes. Nevertheless, our preparation of concentrated polyribosomes devoid of the major 50S core SMN complex convincingly demonstrated the presence of an SMN peak centered on heavy polyribosome fractions (Fig. 1B) . Furthermore, the fact that this fast-sedimenting pool of SMN was shifted toward lighter fractions of the gradient upon treatment with either EDTA or puromycin strongly argues that SMN is physically associated with the translation machinery. SMN is known to interact with several constituents of neuronal mRNPs, including KSRP (20) , hnRNP R/Q (19, 22) and HuD (16) (17) (18) . However, it remains unclear whether these interactions actually take place within the mRNP complexes. Strikingly, we were able to demonstrate, using oligo(dT) affinity purification, that the SMN pool found in concentrated polyribosomes is in fact tightly associated with poly(A)+ mRNP complexes 
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( Fig. 1C) . Nevertheless, more experiments will be needed to determine whether SMN contacts mRNAs directly within mRNPs or through interaction with specific RNA-binding proteins. Although early in vitro studies have documented that SMN is capable of binding RNA directly (48, 49) , evidence of this in cells has remained elusive. Indeed, it was recently demonstrated that it is Gemin5, within the SMN core complex, that contacts directly snRNAs during the snRNP assembly process (50, 51) . Similarly, no direct interaction between SMN and b-actin mRNA could be detected, and it was speculated that SMN mediated its effects on this mRNA through its interaction with hnRNP R (19).
Interestingly, in our experiments, Gemin2 was also found in association with polyribosomes, while in contrast, Gemin8 and Unrip were detected only in lighter fractions, even upon longer immunoblot exposures (Fig. 1A) . Similarly, spliceosomal Sm proteins did not co-fractionate with SMN in heavy polyribosomes, consistent with this sub-population of SMN playing a role in snRNP-independent processes. The architecture of the core SMN complex alone cannot explain these observations as both Gemin2 and Gemin8 are known to contact SMN directly within the core complex, whereas Unrip binding is mediated through Gemin7 and 8 (52 and references therein). This suggests that polysomal SMN might involve a sub-complex with only specific Gemins being present, including at least Gemin2. Although SMN in axons (17, 53, 54) and at sarcomeres in muscles (55) is thought to function in the context of the Gemin-containing core complex, Gemins, in contrast, were previously found to have SMN-independent functions (56). For example, Gemin3 and 4 are known to exist in a distinct complex which functions in the miRNA pathway and co-fractionates with polyribosomes (57, 58) . Intriguingly, Mourelatos and co-workers (57) did not detect SMN or Gemin2 on polyribosomes in their studies, although they did not perform an enrichment as we did in our experiments and treated cells with CHX before loading onto sucrose gradients. Furthermore, they performed their experiments in a human neuronal cell line (Weri), but not of motor neuron origin, suggesting association of SMN with polyribosomes might be cell typespecific. Lastly, a few studies have proposed a role for Gemin5 in translation (59 -61), but again this activity is thought to be SMN-independent. Thus, it will be important, in future experiments, to purify and identify the specific components of the SMN complex present in association with polyribosomes in order to gain a better understanding of its role in this context.
SMN can repress translation
We have first used a generic Luciferase reporter construct to show that SMN can repress translation in a dose-dependent fashion in RRL reactions. Although most of our experiments have been performed using a coupled TnT system, we have confirmed that SMN was having an effect specifically on translation by setting up reactions where the Luciferase reporter mRNA had been in vitro-transcribed separately, quantified and purified (including a DNase I treatment to ensure that no residual plasmid DNA was present) and then added to RRL reactions pre-programmed with either SMN or an unrelated protein (b-Gal). This experimental scheme also allowed us to perform reactions with the translational reporter mRNA not harboring a 5 ′ -Cap modification. The prediction here was that translation initiation should not occur in the absence of a Cap, unless something like an internal ribosome entry site (IRES) is present on the reporter. Surprisingly, although to our knowledge the pGL4 reporter that we used in our experiments does not contain an IRES, we were still able to detect low translational activity in the absence of a Cap structure; and SMN was able to repress this residual activity (Supplementary Material, Fig. S1D ). This residual activity in the absence of a Cap might be due to the fact that the commercial RRLs that were used in these experiments are highly optimized for efficient translation, and this might perhaps bypass the normal requirement for a 5 ′ -Cap on the mRNA. Although at face value this result might suggest that SMN represses translation through a Cap-independent mechanism, it is difficult to speculate without knowing exactly how translation occurs on uncapped mRNA in RRLs.
Our in vitro translation experiments also allowed us to identify molecular determintants required for SMN to repress translation. Strikingly, we demonstrated that a naturally occurring point mutation in the Tudor domain, E134K, was sufficient to completely abrogate the repressive activity of SMN, while deletions in either the N-terminal or C-terminal domains of the protein did not have any effects (Fig. 2B) . We also tested another SMA-causing Tudor mutation at position I116 (I116F), which similarly affected the ability of SMN to repress translation, although to a lesser extent than the E134K mutation (Supplementary Material, Fig. S1C) . We have previously shown that the E134K mutation abolishes binding to arginine-methylated proteins (62) . These results were recently revisited in a more quantitative and structural study, which revealed that the E134 residue participates in a hydrogen bond triangle that serves to stabilize the aromatic cage domain responsible for methylarginine recognition (63) . Interestingly, this study also demonstrated that the I116F mutation behaved similarly to the wild-type protein in terms of its binding to methylated arginines (63) , which could explain why this mutation did not have a strong effect on SMN's activity in repressing translation. Altogether, these results strongly suggest that SMN needs to physically interact, through its Tudor domain, with an arginine-methylated co-factor(s) to repress translation. Furthermore, our demonstration that the E134K mutation does not prevent the association of SMN with polyribosomes (Fig. 5B) suggests that this co-factor is not a component of the basic translational machinery. We thus favor a model where SMN would be tethered to ribosomes through a Tudor-independent mechanism, and would then recruit one or more methylated co-factor(s) to allow for translational repression. SMN in this context would serve to either promote the assembly of this repressive complex and/or help to stabilize it, whereas the co-factor(s) might provide target specificity. Such a mechanism would be highly reminiscent of the chaperoning role that SMN plays in snRNP assembly and is thought to play in neuronal mRNP granules.
Interestingly, interactions between SMN and known translational regulators have previously been reported. For example, an interaction between SMN and FMRP was previously described (21) . FMRP is a neuronal RNA-binding protein known to associate with polyribosomes (64) and repress (65, 66) or activate translation (67) . However, Piazzon and colleagues (21) have shown that the Tudor domain of SMN is dispensable for its interaction with FMRP, strongly arguing that SMN's activity on translation is likely not dependent on FMRP. A novel interaction between SMN and the neuronal RNA-binding protein HuD was recently uncovered (16) (17) (18) . In contrast to FMRP, the interaction with HuD is mediated through the Tudor domain of SMN, and is lost with the E134K mutant allele (17, 18) . However, HuD is a positive regulator of cap-dependent translation, through its concomitant interaction with eIF4A and the poly(A) tail of mRNAs (68) . Thus, it would imply that SMN would somehow prevent or repress HuD's capacity to stimulate translation. Finally, SMN was also found to interact with LSm proteins through its Tudor domain (69 -72) . This family of proteins is mostly known for its roles in mRNA metabolism (73, 74) , but it was postulated they might also regulate translation in some contexts (75 -77) . Although we did not probe for LSm proteins directly, the Y12 antibody is known to recognize an arginine-methylated epitope on LSm4 (69), and we did not detect any signal in polyribosome fractions with the Y12 antibody in our experiments (Fig. 1A) . Di Penta et al. (76) have shown that LSm1 is involved in translational control in dentrites, and although they reported that LSm1 could be found on polyribosomes, they did not detect an interaction with SMN in those fractions. Whether SMN cooperates for this novel function with LSm proteins or other interacting proteins with known roles in translation, like, e.g., hnRNP Q or TIAR (22, 78, 79) , will require further experimentation.
CARM1 is mis-regulated at the translational level in SMA-like conditions
Our detailed analysis clearly indicated that CARM1 is misregulated at the level of mRNA translation in the face of reduced SMN levels: (i) CARM1 mRNA levels do not change between CTRL and DSMN MN1 cells, which rules out regulation at the level of transcription or mRNA stability, (ii) mRNA export is also not affected, (iii) CARM1 protein stability/turnover is similar between the two conditions, (iv) CARM1 mRNAs are shifted toward heavy polyribosomes in DSMN cells, (v) the rate of protein synthesis, as measured by [ 35 S]-methionine incorporation, was higher in DSMN cells. Importantly, CARM1 levels were decreased back to control levels upon rescue of SMN expression in DSMN cells, while no effect was observed with the SMA-causing E134K mutant allele, which parallels what was observed for SMN activity in repressing translation in vitro, and thus argues for a direct role of SMN in CARM1 translational regulation. This demonstration was somewhat complicated by the fact that the effect of SMN on CARM1 translation was independent of its UTRs, suggesting that specificity must somehow be conferred through CARM1 coding sequence. Interestingly, it was recently determined that FMRP also associated through coding sequences with at least some of its mRNA targets, leading to translational repression through reversibly stalling elongating ribosomes (80) . This provided a novel mechanism to reconcile that a translational repressor can seemingly be associated with actively translating heavy polyribosomes (like SMN) and yet repress translation. Nevertheless, we could not formally exclude the potential implication of miRNAs in this process, although the fact that repression did not involve UTRs argues against this possibility since miRNAs targeting coding sequences remain a fairly rare occurrence to date. Strikingly, we were able to show that reducing SMN levels through transient shRNA knock down in a cell line stably expressing a CARM1-GFP cassette resulted in the up-regulation of both endogenous CARM1 and CARM1-GFP fusion proteins (Fig. 6C) , strongly arguing that the coding sequence of CARM1 is sufficient to allow regulation by SMN. Most importantly, we were also able to demonstrate an association between SMN and CARM1 mRNA in RNA immunoprecipitation experiments (Fig. 6D) . Although this approach does not really discriminate between a direct or indirect interaction with RNA, it does lend strong support for a direct implication of SMN in translational regulation of CARM1 mRNA.
SMN depletion did not seem to have a general effect on global translation, as seen in metabolic labeling experiments and polysome profiles ( Fig. 2C and D) . This result strongly argues that SMN likely regulates only a subset of mRNAs. In agreement with the previous observation, a number of proteomic studies have been published in recent years, and most report a fairly limited number of proteins being either up-or down-regulated under SMA conditions (81) (82) (83) . It will obviously be interesting to identify additional mRNA targets that may be regulated by SMN at the level of translation. In this regard, a recent study by Beattie and co-workers (84) has provided evidence suggesting that down-regulation of Plastin3 in SMA might involve a translational mechanism, and this phenomenon was also seemingly independent of UTRs. While this manuscript was in revision, a study by Sendtner and co-workers (85) provided demonstration of misregulated local translation of b-actin mRNA in cultured motoneurons from severe SMA model mice, although it remains unclear whether this was through a direct effect of SMN. It will be interesting to assess whether CARM1 is also locally translated, and regulated by SMN in this context, in motoneuron axons.
CARM1 up-regulation is a novel molecular defect in SMA
We have shown that CARM1 is abnormally up-regulated in the spinal cord of two distinct SMA mouse models and most importantly in primary fibroblasts derived from a severe type I human SMA patient. Interestingly, we have recently characterized a novel regulatory pathway involving CARM1 in a motoneuron-derived cell line (18) . More specifically, we Human Molecular Genetics, 2013, Vol. 22, No. 4 679 observed that CARM1 expression needed to be downregulated to allow cell cycle exit and induction of the full differentiation program. At the molecular level, CARM1 methylation selectively modulated the landscape of mRNA targets bound by HuD and also regulated the interaction between SMN and HuD. Thus, our current findings suggest that SMN, by repressing CARM1 mRNA translation, may in fact be part of a negative feedback loop regulating CARM1 expression in motoneurons. CARM1 is emerging as a crucial player in maintaining progenitor and stem cells in a pluripotent proliferative state (18,86 -89) . In the context of postmitotic motoneurons, one could speculate that high levels of CARM1 may cause abortive re-entry in the cell cycle and contribute to cell death. However, there is accumulating evidence that, in the absence of overt motoneuron loss, reduction of SMN levels leads to various neurogenesis and neuritogenesis defects (at least in specific model system), as well as neuromuscular junction and sensory motor connectivity impairment (19,20,29,33,90 -93) . With this in mind, it is tempting to speculate that an increase in CARM1 activity may result in aberrant arginine methylation of HuD, which would in turn affect the landscape of mRNA targets that it normally regulates (e.g. GAP43, cpg15, tau, nova-1), and in turn may have important consequences for proper maturation and maintenance of neurites and synapses. Finally, we have initiated a screen of validated CARM1 transcriptional and alternative splicing targets and identified so far three that are misregulated in our cell culture model of SMA (Fig. 8) . Most importantly, we have shown that reducing CARM1 expression using shRNA knock down resulted in the reversal of the misregulated profiles observed in DSMN cells, strongly arguing that CARM1 up-regulation was causal in these events. It will obviously be important to expand these observations to a genome-wide analysis and validate our findings with functional readouts in animal models of SMA. In summary, we have uncovered a novel activity for the SMN protein in translational repression, which might be highly relevant to the function of SMN within RNA granules in motoneuron axons. We have also demonstrated that CARM1 up-regulation, through mis-regulated translation, is a novel molecular defect in spinal cord motor neurons from SMA model mice and in cells from a type I SMA patient. Finally, we provide evidence that increased CARM1 levels may provide an alternative molecular mechanism contributing to the aberrant expression profiles contributing to SMA pathogenesis, and may thus represent a novel therapeutic target to tackle this devastating disease.
MATERIALS AND METHODS
Cell culture, treatments and transfection experiments
Motoneuron-derived CTRL MN-1 cells, SMN stable knockdown MN-1 cells (DSMN) and CARM1 stable knockdown MN-1 cells (DCARM1) are described previously (18) . Cells were cultured in DMEM (GIBCO) supplemented with 10% fetal bovine serum and maintained in 2 mg/ml puromycin. The stable MN-1 cell line expressing CARM1-GFP is maintained in G418 antibiotic at 0.5 mg/ml. Primary fibroblast cells from unaffected (GM08333) or from SMA type I patients (GM00232) were obtained from Coriell Cell Repositories. For transient transfection, Lipofectamine and Plus Reagents from Invitrogen were used. Cells were harvested for biochemical analyses 24 h after transfection. SMN-GFP plasmid was constructed by inserting PCR-amplified hSMN1 full-length cDNA flanked by a 5
′ EcoRI site and 3 ′ BamHI site into EcoRI and BamHI sites of pEGFP-N1. SMN-E134K-GFP was generated using overlap extension mutagenesis PCR (94) and inserted into EcoRI and BamHI sites of pEGFP-C1. Puromycin treatment was for 1 h at 10 mg/ml prior to ultracentrifugation in sucrose density gradients. For CARM1 protein stability experiments, cells were treated with 50 mg/ml CHX for the indicated time.
RNA purification, RT-PCR and RT-qPCR
RT-PCR and RT-qPCR were performed essentially as previously described (95) . RNA was extracted by using Trizol (Invitrogen) and treated with rDNase I (DNAfree, Ambion). RT was done by using AMV reverse transcriptase (Promega) and random primers. After the completion of the RT reaction, cDNA samples were diluted to a final concentration of 2.5 ng/ ml. Five microliters of cDNA samples were used per 25 ml PCR or qPCR reactions. PCR was performed by using GoTaq Flexi DNA Polymerase (Promega) and qPCR was performed by using iQ SYBR Green Supermix (Bio-Rad) on a Chromo4 Real-Time Detector (Bio-Rad). The relative amounts of cDNA targets in samples were determined on the basis of the threshold cycle for each PCR product (C t ). For RNA immunoprecipitation assay, the data sets were normalized to input values (percentage of INPUT RNA: 2
, where Ct (Input) is the Cycle Threshold for the Input RNA and Ct (IP) is the Cycle Threshold for the immunoprecipitated RNA. Primers, PCR and qPCR conditions are described in Supplementary Material, Figure S3 . Cytoplasmic and nuclear RNA fractions were prepared as described (96) .
Immunoblotting
The following antibodies were used: CARM1 (A300-421A, Bethyl Laboratories); GAPDH (MMS-580S, Covance); tubulin (T6199, Sigma-Aldrich); SMN (610647, BD Transduction Laboratories); GFP (11814460001, Roche Applied Science); RPL7 (Novus Biologicals, NB100-2269); RPS6 (mAb 2217, Cell Signaling Technology); HA.11 Clone 16B12 (MMS-101P, Covance); Unrip (3G6) (Abcam, ab46784); Gemin2 (2E17) (Abcam, ab6084); Gemin 8 (1F8) (Santa Cruz, sc-130669); PABP (Cell Signaling); FMRP mAb1C3 (97); Y12 hybridoma supernatant (98) was a kind gift from Dr J. Steitz. Anti-myc monoclonal antibody (9E10) was purified from hybridoma supernatant (ATCC). Quantitative analyses were done with the ImageJ software.
Sucrose density ultracentrifugation
Cytoplasmic extracts were analyzed by sedimentation velocity in 15-45% (w/w) linear sucrose gradients as described (64, 99) . For EDTA-mRNPs studies, the cytoplasmic extracts were treated with 30 mM EDTA before analyses on sucrose gradients. For RNA analysis, RNA extraction was performed by mixing 100 ml of each collected fraction with 1 ml of Trizol.
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Oligo(dT) selection of mRNPs
Poly(A)-containing mRNPs present in polyribosomes were selected on oligo(dT) as described (100), with the exception that Dynabeads Oligo(dT) 25 (Invitrogen) were used. Proteins bound to mRNPs were eluted with increasing salt concentrations and analyzed for the presence of SMN and FMRP.
Metabolic labeling and protein synthesis run-on assay
Control and DSMN cell lines were grown for 3 h with serumfree, L-glutamine-free-, L-cystein-free and L-methionine-free media (319-045-EL, Wisent). After this incubation time, the medium was removed and supplemented with 10% fetal bovine serum, penicillin -streptomycin as well as L-glutamine and L-cystein, and [
35 S]-methionine at 40 mCi/ ml was added for the indicated time. Then, cells were harvested and lysed with RIPA buffer. For protein synthesis run-on experiments, after a pre-clearing step (30 min at 48C), an aliquot was taken (whole-cell lysate, WCL) and the rest of the supernatant was immunoprecipitated 1 h at 48C with 2 mg of CARM1 antibody coupled with Protein A/G PLUS Agarose (Santa Cruz Biotechnology). Beads were washed three times, incubated with Laemmli sample buffer for 10 min at 958C and separated by SDS -PAGE. After electrophoresis, the gels were dried at 808C and exposed to autoradiography film at 2808C.
In vitro TnT
Experiments were done using the TnT T7 Coupled Reticulocyte kit (L4610, Promega). TnT reactions were setup in one or two steps whether we had to produce or not proteins of interest to be tested. Indeed, when the GST fusion proteins were available, the TnT assay required only one step. In the case of the two-step TnT assay, the first step was used to preproduce the different proteins of interest. The first reaction was performed for 1 h and 30 min at 308C in 25 ml containing: 12.5 ml of lysates, 1 ml of TnT reaction buffer, 0.5 ml of TnT T7 polymerase, 0.25 ml of amino acid mixture minus leucine, 0.25 ml of amino acid mixture minus methionine, 0.5 ml of recombinant RNasin ribonuclease inhibitor (Promega), 2.5 mg of plasmid DNA expressing the protein of interest and water up to 25 ml. After the completion of the initial step, 25 ml of TnT reaction containing this time the Firefly Luciferase plasmid DNA was added to the first reaction. This new reaction was then incubated at 308C (30 or 60 min) before quantifying the Firefly Luciferase activity using the Dual-Luciferase Reporter Assay Chemistry (E1910, Promega), which relies on the oxidation of beetle Luciferin in the presence of ATP, Mg 2+ and O 2 . Where Renilla Luciferase activity needed to be measured, the same kit was used, but with coelenterazine and O 2 as substrates, following the addition of 'Stop & Glo' reagent to quench the Firefly enzyme reaction.
In vitro RNA synthesis and Luciferase assay
For in vitro RNA synthesis of Capped RNA transcript, the reaction was performed for 1 h at 378C in 50 ml containing: 10 ml of Transcription Optimized 5× buffer (Promega); 5 ml of 0.1 M DTT; 50 units of recombinant RNasin ribonuclease inhibitor (Promega); rNTPs (5 mM rATP, 5 mM rUTP, 5 mM rCTP, 0.5 mM rGTP); 2.5 ml of 10 mM Ribo m 7 G Cap analog; 300 ng of Firefly Luciferase linearized DNA template; 40 units of T7 RNA Polymerase (Promega) and water. To increase the yield of RNA, we repeated the incubation step (1 h at 378C) with the addition of 40 extra units of T7 RNA polymerase. For in vitro RNA synthesis of non-Capped RNA transcript, the reaction is similar excepted that the Ribo m 7 G Cap analog was substituted by water. Once the Capped and nonCapped RNAs were synthesized, reactions were subjected first to a DNase treatment (DNAfree, Ambion) followed by an RNeasy mini kit (Qiagen) purification. In parallel of the in vitro RNA synthesis, a TnT reaction was used to preproduce either SMN-E134K-myc or SMN-myc. For the last step, 10 ml of purified RNA template was added to a 25 ml of TnT reaction. This latter TnT reaction was then added to the 25 ml of TnT reaction pre-producing either SMN-E134K-myc or SMN-myc and was incubated for 30 min at 308C before quantifying the Firefly Luciferase activity with the Dual-Luciferase Reporter Assay Kit (Promega).
RNA immunoprecipitation experiment
These experiments were performed essentially as described previously (101) . Total extracts from one 10 cm dish of cells were always prepared in parallel to measure the levels of the different RNA molecules (Input). RNA was immunoprecipitated using 3 mg of SMN antibody (610647, BD Transduction Laboratories) and 3 mg of control IgG (sc-2025, Santa Cruz). We used 5 ml of immunoprecipitate (diluted 1:10) or 12.5 ng (5 ml) of Input RNA in 25 ml qPCR reactions.
Immunofluorescence in spinal cord sections
Spinal cords were removed and fixed overnight in 4% PFA (Electron Microscopy Sciences). Following equilibration in 30% sucrose, tissue was embedded in 30% sucrose/50% OCT and sectioned at 14 mm. Sections were permeabilized in 0.5% Triton X (Sigma-Aldrich) and blocked in 4% BSA. Primary antibodies (CARM1, Bethyl Laboratories; Neurofilament 200, Covance) were applied overnight at 1:250 at 48C. Secondary antibodies (Alexa 488-conjugated mouse antirabbit; Alexa 555-conjugated goat anti-mouse, Invitrogen) were applied at 1:250 for 2 h and nuclei were labeled with DAPI (5 min, 1:1000). For quantification, motor neurons were identified by SMI 32 labeling, a cell body .20 mm and location in the anterior horn. All images were taken using the same laser settings. Expression levels were quantified using the mean gray value function in the ImageJ software.
Animal experimentation
Type I SMA model mice containing two human SMN2 transgenes and the mouse Smn knock-out were purchased from The Jackson Laboratory and genotyped as previously described (102) to obtain severe SMA-like phenotype (Smn 2/2 ;SMN2) or control (Smn +/+ ;SMN2) and asymptomatic carriers (Smn +/2 ;SMN2). These colonies were maintained in F.C.'s facility and the care and treatment of animals followed the French national authority guidelines for the detention, use and the ethical treatment of laboratory animals and was approved by the local ethic committee (number P2.CC.034.07). The Smn 2B/2 mice were established in R.K.'s laboratory and maintained in the University of Ottawa animal facility on a C57BL/6 × CD1 hybrid background. The 2B mutation consists of a substitution of three nucleotides in the exon splicing enhancer of exon 7 (103, 104) . All animal procedures were performed in accordance with institutional guidelines (Animal Care and Veterinary Services, University of Ottawa).
Statistical analysis
For statistical analysis, Student's t-tests or a Mann -WhitneyWilcoxon test was used. However, when three or more groups were compared, a one-way ANOVA and post hoc Tukey analysis was performed. In the figures, a single asterisk shows P , 0.05, a double asterisk shows P , 0.01, a triple asterisk shows P , 0.001, a quadruple asterisk shows P , 0.0001. Analyses were realized with the Graphpad Prism 6 software.
